In ovarian cancers, HER2 (human epidermal growth factor receptor 2, a receptor involved in proliferation, migration, and survival) and KDM6B expressions were correlated to poor prognosis and a low survival rate. This evidence concerns the gene ERBB2 and ovarian carcinoma.